Clinical Trial Update: Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) [Phase 2]

View source ↗

Summary

Phase 2 MODIFI-RC-I trial evaluating modified long-course radiotherapy followed by chemotherapy and a PD-1 inhibitor for MSS/pMMR high-risk mid/low rectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• PD-1 inhibitor

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Rectal Cancer, Neoadjuvant Therapies | Phase 2 | Status: RECRUITING